List of Antiviral Therapies Companies in Switzerland - 5

DiNAQOR is a genetic medicine platform company pioneering early-stage drug development and manufacturing to advance promising gene therapies to the clinic. Our patent-protected, industry leading platform is designed to overcome the challenges and limitations of advanced gene therapy development by using proprietary engineered heart tissue technology (EHT), a novel Loco-Regional Perfusion system (LRP) and a fully integrated manufacturing solution. Our company is headquartered in the Greater Zurich Area, Switzerland, with additional presence in Laguna Hills, California and Hamburg, Germany.

Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.

Nouscom is a private clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors with demonstrated high immunogenicity in patients. Nouscom’s clinical pipeline includes NOUS-209, an off-the-shelf cancer immunotherapy assessing the efficacy of the treatment in advanced MSI-H CRC patients in combination with pembrolizumab in randomized phase 2 trials. A Phase 1b study of NOUS-209 monotherapy in Lynch Syndrome Carriers with potential to ‘intercept cancer’ before it occurs is running in collaboration with the National Cancer Institute. Nouscom's second clinical program is NOUS-PEV, a personalized cancer immunotherapy for the treatment of advanced cancers with great unmet medical need. Nouscom has exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy, to Janssen Oncology. The program is under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms. Nouscom was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy. The company is backed by international life sciences investors: 5AM, Andera Partners, Bpifrance, EQT Life Sciences, Indaco Venture Partners, M Ventures, Panakes Partners, Revelation Partners, Versant Ventures, and XGen Ventures and has raised a total of $130M to date. For more information on Nouscom, please visit the company’s website at www.nouscom.com

Quercis Pharma AG is leveraging its novel antithrombotic platform to deliver safe and innovative treatments to patients with a variety of complex diseases that are poorly addressed by today’s medicines and is committed to providing affordable access to these potentially life-saving therapies

Redbiotec is a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Founded in 2006 as a spin-off of the Swiss Federal Institute of Technology in Zurich (ETH Zurich), the company has won several awards, including the renowned W.A. De Vigier Award. The company is successful in producing key proteins and genetic materials for biopharma and food industry thanks to a dedicated scientific team with expertise in multiple disciplines from immunology and microbial engineering to protein engineering. Presently, Redbiotec is involved in the alternative-dairy development. We are using precise fermentation in different expression platforms to recombinantly produce milk proteins, such as caseins, with high yield and their post-translational modifications. We actively evaluate partnering opportunities with the goal of reinforcing our portfolio, and/or to add value to the process developed by our collaboration partners. We welcome strategic partnerships to use our recombinant proteins for animal-free food products and to increase the impact of our technology platforms.